Since the inefficiency of CD22-targeting drugs against CLL may be explained by the low expression of CD22 protein on CLL B cells (20, 21), the combination of IRF4 inhibition and CD22-targeted therapy (e.g., immunotherapy using antibody or chimeric antigen receptor) may be worth exploring. This evidence concerns the gene CD22 and B-cell chronic lymphocytic leukemia.